|
Name |
Tricosane
|
Molecular Formula | C23H48 | |
IUPAC Name* |
tricosane
|
|
SMILES |
CCCCCCCCCCCCCCCCCCCCCCC
|
|
InChI |
InChI=1S/C23H48/c1-3-5-7-9-11-13-15-17-19-21-23-22-20-18-16-14-12-10-8-6-4-2/h3-23H2,1-2H3
|
|
InChIKey |
FIGVVZUWCLSUEI-UHFFFAOYSA-N
|
|
Synonyms |
TRICOSANE; n-Tricosane; 638-67-5; Docosane, methyl-; Tricosan; T166B8R1VC; CH3-[CH2]21-CH3; NSC-78487; Tricosane, analytical standard; MFCD00009350; UNII-T166B8R1VC; EINECS 211-347-4; NSC 78487; Tricosane, 99%; AI3-35917; DTXSID7047699; CHEBI:32934; HSDB 8353; NSC78487; ZINC6920416; LMFA11000589; AKOS015843179; AS-56122; DB-054568; CS-0188393; FT-0632718; T0568; TRICOSANE [STANDARD MATERIAL FOR GC]; C17433; T72756; A834566; Q150977; D3CD819C-C009-4DE8-8A12-BEFA098575B2
|
|
CAS | 638-67-5 | |
PubChem CID | 12534 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 324.6 | ALogp: | 12.1 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 20 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 23 | QED Weighted: | 0.171 |
Caco-2 Permeability: | -5.135 | MDCK Permeability: | 0.00000504 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.139 |
30% Bioavailability (F30%): | 1 |
Blood-Brain-Barrier Penetration (BBB): | 0.016 | Plasma Protein Binding (PPB): | 98.75% |
Volume Distribution (VD): | 4.646 | Fu: | 1.11% |
CYP1A2-inhibitor: | 0.068 | CYP1A2-substrate: | 0.151 |
CYP2C19-inhibitor: | 0.175 | CYP2C19-substrate: | 0.059 |
CYP2C9-inhibitor: | 0.038 | CYP2C9-substrate: | 0.966 |
CYP2D6-inhibitor: | 0.145 | CYP2D6-substrate: | 0.028 |
CYP3A4-inhibitor: | 0.163 | CYP3A4-substrate: | 0.022 |
Clearance (CL): | 4.442 | Half-life (T1/2): | 0.019 |
hERG Blockers: | 0.381 | Human Hepatotoxicity (H-HT): | 0.005 |
Drug-inuced Liver Injury (DILI): | 0.391 | AMES Toxicity: | 0.008 |
Rat Oral Acute Toxicity: | 0.02 | Maximum Recommended Daily Dose: | 0.038 |
Skin Sensitization: | 0.97 | Carcinogencity: | 0.022 |
Eye Corrosion: | 0.996 | Eye Irritation: | 0.929 |
Respiratory Toxicity: | 0.322 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000446 | 0.957 | D00AOJ | 0.861 | ||||
ENC000432 | 0.955 | D07ILQ | 0.512 | ||||
ENC000433 | 0.918 | D00STJ | 0.496 | ||||
ENC000430 | 0.910 | D00FGR | 0.495 | ||||
ENC000434 | 0.882 | D0Z5SM | 0.458 | ||||
ENC000285 | 0.866 | D05ATI | 0.390 | ||||
ENC000750 | 0.861 | D0O1PH | 0.385 | ||||
ENC000449 | 0.861 | D0T9TJ | 0.375 | ||||
ENC000401 | 0.848 | D00MLW | 0.348 | ||||
ENC001173 | 0.829 | D0Z1QC | 0.331 |